Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization by Farhood, B. et al.
Vol:.(1234567890)
Clinical and Translational Oncology (2019) 21:268–279
https://doi.org/10.1007/s12094-018-1934-0
1 3
REVIEW ARTICLE
Melatonin as an adjuvant in radiotherapy for radioprotection 
and radiosensitization
B. Farhood1 · N. H. Goradel2 · K. Mortezaee3 · N. Khanlarkhani4 · E. Salehi4 · M. S. Nashtaei4,5 · H. Mirtavoos‑mahyari6 · 
E. Motevaseli7 · D. Shabeeb8,9 · A. E. Musa8,10 · M. Najafi11 
Received: 13 May 2018 / Accepted: 2 August 2018 / Published online: 22 August 2018 
© Federación de Sociedades Españolas de Oncología (FESEO) 2018
Abstract
It is estimated that more than half of cancer patients undergo radiotherapy during the course of their treatment. Despite its 
beneficial therapeutic effects on tumor cells, exposure to high doses of ionizing radiation (IR) is associated with several side 
effects. Although improvements in radiotherapy techniques and instruments could reduce these side effects, there are still 
important concerns for cancer patients. For several years, scientists have been trying to modulate tumor and normal tissue 
responses to IR, leading to an increase in therapeutic ratio. So far, several types of radioprotectors and radiosensitizers have 
been investigated in experimental studies. However, high toxicity of chemical sensitizers or possible tumor protection by 
radioprotectors creates a doubt for their clinical applications. On the other hand, the protective effects of these radioprotec-
tors or sensitizer effects of radiosensitizers may limit some type of cancers. Hence, the development of some radioprotectors 
without any protective effect on tumor cells or low toxic radiosensitizers can help improve therapeutic ratio with less side 
effects. Melatonin as a natural body hormone is a potent antioxidant and anti-inflammatory agent that shows some anti-
cancer properties. It is able to neutralize different types of free radicals produced by IR or pro-oxidant enzymes which are 
activated following exposure to IR and plays a key role in the protection of normal tissues. In addition, melatonin has shown 
the ability to inhibit long-term changes in inflammatory responses at different levels, thereby ameliorating late side effects of 
radiotherapy. Fortunately, in contrast to classic antioxidants, some in vitro studies have revealed that melatonin has a potent 
anti-tumor activity when used alongside irradiation. However, the mechanisms of its radiosensitive effect remain to be elu-
cidated. Studies suggested that the activation of pro-apoptosis gene, such as p53, changes in the metabolism of tumor cells, 
suppression of DNA repair responses as well as changes in biosynthesis of estrogen in breast cancer cells are involved in this 
process. In this review, we describe the molecular mechanisms for radioprotection and radiosensitizer effects of melatonin. 
Furthermore, some other proposed mechanisms that may be involved are presented.
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Introduction
For several years, scientists have been looking for strategies 
to reduce early and late effects of radiotherapy, as well as 
increasing tumor response to radiation treatment. Either of 
these aims can help improve therapeutic ratio, leading to 
the reduction of side effects and increasing survival rate of 
cancer patients [1]. The use of radioprotectors and radio-
sensitizers is two interesting strategies for alleviating side 
effects to normal tissues and reducing tumor resistance [2]. 
So far, several types of radioprotectors and radiosensitizers 
have been tested in experimental studies [3, 4]. An appropri-
ate radioprotector should protect normal tissues selectively 
without adverse effects on tumor response. In addition, a 
good radiosensitizer should not increase the toxicity of nor-
mal tissues [2, 5].
Amifostine, a Food and Drug Administration (FDA) 
approved radioprotector, has been widely examined and 
used in clinical radiotherapy [6, 7]. It has shown the abil-
ity to protect various normal tissues such as oral mucosa 
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and salivary glands in head and neck cancer, bone mar-
row, lungs, intestines and kidneys. [8, 9]. Several studies 
have confirmed that amifostine protects these organs selec-
tively without any adverse effect on tumor response. How-
ever, amifostine has some side effects such as nausea and 
vomiting, which may lead to its discontinuation during the 
course of radiotherapy [10–12]. It is important to note that 
amifostine cannot protect all human organs against toxic 
effects of ionizing radiation (IR) [13] and, hence, the need 
for further research to discover alternative agents with both 
radioprotective and radiosensitization properties in radiation 
therapy applications.
Melatonin is a natural product of the human body that 
has shown impressive properties for protection against toxic 
effects of anti-cancer modalities such as chemotherapy and 
radiotherapy [14–16]. It is mostly secreted by the pineal 
gland in the brain, while several studies have identified other 
sources such as lymphocytes, retina and gastrointestinal sys-
tem [17–19]. Although the major effect of melatonin in the 
body is control of sleep and wake cycle, several studies have 
shown that it has other interesting properties such as anti-
oxidant, anti-inflammatory and anti-aging effects [20–22]. 
In the last two decades, several studies have been conducted 
to investigate the radioprotective effects of melatonin in dif-
ferent cells and organs. Due to the ease with which mela-
tonin penetrates all cell types in the body, it can protect dif-
ferent organs against various side effects of radiation [23]. 
In recent years, some studies have shown that melatonin 
sensitizes some tumor cells to radiation. Both radioprotec-
tive and radiosensitization effects of melatonin make it an 
ideal candidate for use as an adjuvant in radiotherapy. On the 
other hand, the natural metabolisms of melatonin in human 
body cells lead to low toxicity compared to other chemical 
products such as amifostine [24]. In this review, we clarify 
the mechanisms through which melatonin can act as both 
radioprotector and radiosensitizer as well as possible future 
applications in cancer radiotherapy.
Radiation‑induced DNA damage and cell 
death
DNA is the most crucial target for toxic effects of radiation. 
After transmission of an ionizing radiation from vital cells, 
it may interact with DNA directly, leading to chromosomal 
aberrations or cells death. Although, more than two-third of 
toxic effects of ionizing radiation results from the produc-
tion of free radical due to interaction of ionizing radiations 
with water molecules [25]. Free radicals including reactive 
oxygen species (ROS) and reactive nitrogen species are 
very active molecules that are able to attack DNA and other 
vital organelles within cells. If DNA damages overwhelm 
the responses, it may lead to cell death or development of 
neoplasia [26].
It has been confirmed that radiation can trigger cell death 
through different mechanisms such as apoptosis, mitotic 
catastrophe, necrosis, necroptosis, autophagy, and senes-
cence [27]. The type of cell death depends on the cell type 
[28]. Furthermore, as radiation dose increases, necrosis is 
also increased [29]. After DNA damage and cell death fol-
lowing irradiation, some danger alarms are released from 
damaged cells. Danger alarms can be recognized by mac-
rophages and lymphocytes, leading to several signaling path-
ways involved in inflammation, DNA repair and reduction/
oxidation (redox) metabolism [30–32]. These processes 
are associated with a massive production of free radicals 
including ROS and NO, as well as an increase in the level 
of several cytokines and chemokines such as TNF-α, TGF-
β, IL-1, IL-4, IL-6, IL-8, IL-13, and others [33]. Moreover, 
these changes can cause suppression of antioxidant defense 
in cells, leading to more oxidative stress, DNA breaks and 
cell death [34–36].
Melatonin as a radioprotector
For more than 2 decades, the radioprotective effect of mela-
tonin has been confirmed, firstly by in vitro studies [37, 38]. 
Several in vivo and in vitro studies have been conducted to 
investigate its possible protection on different cells/organs. 
Melatonin has shown ability to alleviate various cytotoxic 
effects of IR such as DNA damage, apoptosis, inflammation, 
fibrosis, cataract, infertility and others [39]. Various studies 
have shown that melatonin can cause protection without any 
cytotoxic effect on the normal functions of other organs. It 
has shown radioprotection via some mechanisms such as 
neutralization of free radicals, boost response to DNA dam-
age and amelioration of inflammatory responses through 
modulation of several signaling pathways that are involved 
in this process.
Melatonin and radiation‑induced oxidative stress
Several studies have revealed the potent antioxidant effect of 
melatonin against various toxic agents such as IR, chemo-
therapy agents, metals and others [40]. Studies have pro-
posed that the antioxidant effect of melatonin is as a result 
of two different processes known as the direct and indirect 
effects. The direct effect is due to scavenging free radicals 
such as reactive oxygen and nitrogen species while its indi-
rect antioxidant effect results from several changes in gene 
transcription as well as the activities of antioxidants and 
ROS/NO producing enzymes [41–43]. Several in vitro and 
in vivo studies have shown that treatment with melatonin 
before exposure to IR can alleviate oxidative injury via 
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upregulation of superoxide dismutase (SOD), glutathione 
(GSH), glutathione peroxidase (Gpx), and catalase (CAT) 
in different cells/organs [44–50]. It has been proposed that 
some upstream genes such as nrf2 [nuclear factor erythroid 
2 (NF-E2)-related factor 2] or TGF-β are involved in upregu-
lating and downregulating antioxidant enzymes. After inter-
action of free radicals with nrf2, it is upregulated, leading 
to the stimulation of antioxidant enzymes [51]. On the other 
hand, increased level of TGF-β which is predictable after 
irradiation may suppress SOD activity through upregula-
tion of mir21 [52, 53]. Melatonin, via stimulation of NRF2-
dependent pathways, can regulate antioxidant defense and 
neutralize free radicals [54, 55].
Another important antioxidant effect of melatonin is 
related to its inhibitory effects on ROS/NO producing 
enzymes. Melatonin has shown ability to attenuate COX-2 
and iNOS enzyme expression in rat’s lung tissue, leading 
to the reduction of oxidative DNA [56]. Some recent stud-
ies have shown that redox activation by mitochondria is a 
main source of ROS production following exposure to IR 
[57–59]. This is associated with genomic instability and 
death of stem cells in critical organs such as hematopoi-
etic and gastrointestinal system, leading to acute radiation 
syndrome and death [60, 61]. Melatonin has been proposed 
as mitochondria targeting agents, with the ability to neu-
tralize mitochondria ROS via improvement in oxidative 
phosphorylation efficiency and electron leakage reduction 
[62]. These properties may make melatonin a potent radia-
tion mitigator via modulation of ROS/NO metabolism after 
exposure to IR [63].
Melatonin modulates radiation‑induced DNA 
damage/cell death and subsequent inflammation
For over two decades, it has been shown that melatonin 
protects against IR-induced DNA damage [37, 64]. In 
1998, Vijayalaxmi et  al. proposed that melatonin via 
scavenging of IR-induced ROS production and activa-
tion of DNA repair enzymes protects cells against IR 
[38]. In recent years, it has been shown that melatonin via 
modulation of DNA damage response can alleviate toxic 
effect of IR, leading to reduced cell death [65]. A study 
by Rezapoor et al. has shown that administering melatonin 
before whole body irradiation enhances BER response in 
circulating lymphocytes. After injecting melatonin, they 
irradiated rats with 2 or 8 Gy X-ray and then evaluated the 
expression of genes involved in BER pathway, including 
Xrcc1, 8-oxoguanine glycosylase1 (Ogg1), and Apex1. 
Their results showed that melatonin treatment augments 
the expression of all mentioned genes. In addition, pre-
treatment with melatonin increases the expression of all 
three genes compared to irradiated non-treated rats. These 
changes were more obvious for 2 Gy, while stimulation 
of all genes was lower when melatonin was administered 
before exposure to 8 Gy [66]. Other studies proposed 
that pre-treatment with melatonin is able to enhance the 
expression of genes involved in other DNA repair path-
ways, including non-homologous end joining (NHEJ) and 
homologous recombination (HR) [67–69].
In addition to DNA repair modulation, melatonin has 
shown ability to change genes involved in apoptosis. The 
most common regulatory genes involved in apoptosis fol-
lowing exposure to radiation are Bcl-2 and Bax [70]. After 
exposure to IR, downregulation of Bcl-2 and upregulation 
of Bax stimulate apoptosis via stimulation of caspase-3 
and release of cytochrome C from the mitochondria. 
Mohseni et al. evaluated the anti-apoptosis role of mela-
tonin on rat’s peripheral blood lymphocytes. Their results 
showed that melatonin reduces apoptosis via reduction of 
bax/bcl-2 ratio. This was more obvious for higher doses of 
melatonin [71]. Similar results were obtained in an in vitro 
study by Jang et al. [72]. Khan et al. showed that pre-
treatment with melatonin before irradiation with a lethal 
dose of gamma rays led to 100% survival and preserva-
tion of hematopoietic and gastrointestinal systems in mice. 
They showed that melatonin reversed the upregulation of 
Bax and p53 as pro-apoptosis genes and elevates Bcl-2 in 
these organs [73].
In addition to apoptosis in highly radiosensitive organs 
such as the bone marrows, necrosis and apoptosis in other 
organs can initiate some signaling pathways, leading to 
inflammation and fibrosis. The necrosis to apoptosis ratio 
has a direct relation with the radiation dose. Therefore, 
with increasing dose as can be seen in stereotactic tech-
niques, the incidence of necrosis and inflammation also 
increases. This is very crucial for some organs such as 
lung, heart, brain, skin, gastrointestinal and vascular. Mel-
atonin is able to reduce the incidence of necrosis and sub-
sequent inflammatory responses following exposure to IR. 
Administering melatonin to rats has shown amelioration of 
neuronal necrosis and degeneration, leading to reduction 
of edema and histopathological changes in the brain [74]. 
NF-κB/NLRP3 inflammasome pathway is an important 
signaling pathway involved in the secretion of IL-1 and 
inflammatory mediators following radiotherapy. Animal 
studies have shown that melatonin through blunting of this 
pathway alleviates mucositis, attenuates accumulation of 
inflammatory cells, and reduces bleeding in the intestine 
and tongue [75, 76]. The protective effect of melatonin on 
radiotherapy induced mucositis has been confirmed for 
head and neck cancer patients without any interruption 
on treatment outcomes [77]. It has also been confirmed 
that melatonin can alleviate radiation-induced inflamma-
tory and fibrosis markers in the lung, heart, skin, and brain 
[78–81] (Table 1; Fig. 1). 
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Melatonin as a radiosensitizer
In addition to the potent radioprotective effects of melatonin, 
some studies in recent years have proposed that melatonin 
is able to increase the therapeutic effects of radiotherapy as 
well as chemotherapy. The most important concern for clini-
cal application of radioprotectors is the possible protection 
of tumor cells, although melatonin has proved differently 
and, hence, facilitating its clinical use for cancer patients 
undergoing radiotherapy. Although, studies involving the 
use of melatonin as a radiosensitizer are very limited, some 
experiments have shown promising results.
Escames et al. showed that melatonin has a synergic 
effect on the therapeutic outcomes of chemotherapy and 
radiotherapy on head and neck cancer cells. They used 
Cal-27 cells to induce tumor xenografts in nude mice. The 
tumor xenografts were irradiated with 8 Gy followed by 
apoptosis and proliferation evaluation. Results showed the 
inhibition of tumor growth in this in vivo tumor xeno-
graft model. Moreover, this study showed that in in vitro 
models of Cal-27 and SCC-9 tongue cell lines, treatment 
with melatonin had a synergic effect on the outcomes of 
chemotherapy and radiotherapy [82]. Although studies on 
the synergic effect of melatonin on the responses of cancer 
cells to IR are very limited, various studies have shown 
that melatonin can improve tumor response to therapy. The 
best example is therapeutic effects of melatonin on breast 
and prostate cancer cells.
Table 1  Mechanisms for radioprotective effects of melatonin
Route Cells/tissues Effect Mechanisms References
In vitro Lymphocyte T Neutralization of ROS/NO Direct interaction with free radicals, stimulation of anti-
oxidant enzymes
[38]
Rat Lymphocyte T Activation of DNA repair enzymes Upregulation of Ogg1 and BER, HR and NHEJ pathway [67–69]
Mice Intestine, tongue Suppression of chronic inflammation Inhibition of NF-κB/NLRP3 inflammasome [75, 76]
Rat Lymphocyte T Suppression of apoptosis Increased Bcl-2/Bax ratio [73]
Fig. 1  Mechanisms of radioprotection by melatonin. Melatonin is 
able to neutralize-free radicals that are produced by IR or pro-oxidant 
enzymes. Furthermore, it suppresses inflammatory signaling path-
ways in different levels, leading to alleviation of long lasting effects 
of radiation. Melatonin via inhibition of chronic oxidative and nitra-
tive DNA damage improves genomic stability, thereby reducing the 
risk of carcinogenesis
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Evidences on synergic effects of melatonin 
with radiotherapy
Reduction of DNA repair capacity in tumor cells
Several evidences have revealed that DNA damage 
responses in tumor cells potently impact therapeutic effi-
cacy. Studies have been conducted to target DNA repair 
mechanisms in cancer cells, thus improving the therapeutic 
response to radiotherapy or chemotherapy [83]. Gonzalez 
et al. showed that pre-treatment with melatonin attenuates 
DNA repair response following exposure to radiation in 
MCF-7 cancer cells. In this study, MCF-7 human breast 
cancer cells were incubated in different concentrations of 
melatonin for 1 week. After irradiation, cells were cul-
tured in same concentrations for 3 or 6 days, followed 
by evaluation of proliferation and DNA damage response. 
Results showed that pre-treatment with melatonin reduces 
the proliferation of MCF-7 cells, while post-treatment had 
no effect. The most potent effect for different doses of 
melatonin was found in 1 nM. Further analysis showed 
that pre-treatment with melatonin led to a decrease in the 
number of cells in S phase. In addition, treatment with 
melatonin inhibited the expression of RAD51 and DNA-
PKcs compared to irradiation of cells only. Similar to cell 
proliferation, 1 nM was more effective for the suppression 
of DNA repair enzymes [84].
Switch from glycolysis to oxidative phosphorylation
One of the most important differences between normal 
and tumor cells is the difference in metabolism. Energy 
production by normal cells is mainly due to cancer cells’ 
dependence on oxidative phosphorylation, while glycoly-
sis is the main source of ATP production in cancer cells to 
maintain proliferation and survival. Some studies proposed 
that abnormal increase in glycolysis is as a result of muta-
tions in mitochondrial DNA (mtDNA), hypoxia in tumor 
cells as well as oncogenes [85, 86]. Increased glycolysis to 
oxidative phosphorylation ratio in tumor cells is associated 
with tumor resistance to therapy procedures such as radio-
therapy [87]. On the other hand, some studies have shown 
that a switch from glycolysis to oxidative phosphorylation 
can increase therapeutic ratio [88]. For example, increased 
oxidative phosphorylation augments apoptosis through 
TRAIL (TNF-related apoptosis-inducing ligand) in mantle 
cell lymphoma cells [89]. Melanoma cells have also shown 
similar results [90]. A study by Escames et al. showed 
that melatonin is able to stimulate oxidative phosphoryla-
tion in Cal-27 cell lines. They evaluated the treatment of 
head and neck cancer cells and also treated tumor-bearing 
mice with melatonin. Results of this study showed that 
treatment with melatonin induces aerobic metabolism and 
reduces glycolysis, leading to elevated mitochondrial ROS 
production and decreased proliferation [91].
Modulation of estrogen biosynthesis
Biosynthesis of estrogen has a key role in the development 
of breast cancer. Estrogen is able to stimulate cell prolifera-
tion via their receptor and also provokes genomic instability 
through stimulation of metabolism [92]. These changes are 
associated with tumorigenesis in breast epithelial cells [93]. 
On the other hand, some reports suggest that the low level of 
melatonin in women is related to higher risk of breast cancer 
incidence [94]. Moreover, melatonin has been proposed as 
a potent agent against initiation and development of breast 
cancer [95]. Studies have reported that melatonin through 
its MT1 receptor inhibits estrogen receptor alpha (ERα) in 
human breast cancer cells [96, 97]. In addition, melatonin 
disrupts the binding of ERα-calmodulin (CaM) complex 
to DNA as well as preventing the transcription of ERα in 
MCF-7 cells [98, 99].
González et al. showed that melatonin through changes 
in estrogen biosynthesis can sensitize human MCF-7 cells 
to ionizing radiation. At first, MCF-7 cells were incubated 
for 7 days in different concentrations of melatonin. After 
irradiation, cells were cultured for 1 week and then the 
effect of melatonin on aromatase (an enzyme responsible 
for biosynthesis of estrogen) regulation was evaluated. 
Results indicated that after irradiating the cells, the activity 
of aromatase was suppressed by 40%. Interestingly, treat-
ment of MCF-7 cells with melatonin had a synergic effect 
on the inhibition of aromatase activity. They showed that 
treatment with 1 mM or 1 nM before exposure to radiation 
can suppress aromatase activity up to 70%. However, treat-
ment of cells with 10 μM of melatonin also had synergic 
effect. However, it was less effective compared to 1 mM or 
1 nM. This study showed the ability of melatonin to sup-
press other major sources of estrogen in breast cancer such 
as estrone sulfatase and 17β-Hydroxysteroid dehydrogenase 
1. Results showed that increased inhibition of these enzymes 
was associated with decreased cell survival [100]. A possi-
ble pathway for the suppression of aromatase by melatonin 
is cyclooxygenase-2 (COX-2) [101]. Targeting COX-2 has 
been proposed for sensitization of various types of cancers, 
as well as mitigation of normal tissues [102].
Stimulation of p53 and apoptosis
In addition to the protection of normal cells against cell death, 
some studies have shown that melatonin has ability to induce 
apoptosis in cancer cells. p53 plays a pivotal role in inducing 
apoptosis in tumor cells. Due to the mutated form of p53 in 
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most cancers, these cells can escape from apoptosis, leading 
to tumorigenesis. Stimulation of p53 gene regulation has been 
proposed as a strategy for sensitization of cancer cells to apop-
tosis. Melatonin stimulates apoptosis via upregulation of p53. 
This is mainly mediated by inhibition of MDM2. In addition, 
suppression of sirt1 by melatonin is another pathway for induc-
ing apoptosis in cancer cells [103, 104]. Cucina et al. showed 
that there are two different pathways for apoptosis in MCF-7 
cells, including early p53/MDM2 dependent and late TGF-β 
dependent pathways. Furthermore, they showed that melatonin 
can induce apoptosis through both mentioned pathways [105]. 
Melatonin can augment the induction of apoptosis in cancer 
cells by doxorubicin or other chemotherapy agents such as 
docetaxel 5-fluorouracil (5-FU) and cisplatin [106–108].
González et al. evaluated the effect of 1 mM, 10 μM or 
1 nM of melatonin on p53 gene expression in MCF-7 cells 
following exposure to radiation. Cells were treated with mela-
tonin for 7 days and then irradiated on the 8th day. Six hours 
after irradiation, cells were cultured and the expression of p53 
was detected. Results showed that irradiation alone caused 
twofold increase in p53 gene expression. Furthermore, all used 
melatonin doses caused more upregulation of p53 compared to 
irradiation alone. Interestingly, the physiological concentration 
of 1 nM melatonin was more effective in the upregulation of 
p53 compared to 1 mM or 10 μM. These changes were asso-
ciated with decreased cell survival [100]. An in vitro study 
by Jang et al. revealed the effect of melatonin treatment on 
apoptosis induction in two normal and tumoral cell lines. They 
revealed that the addition of melatonin to mice splenocyte cells 
reduced the induction of apoptosis due to increased Bcl-2 and 
reduced p53 and Bax expression. By contrast, when Jurkat 
leukemia cells were treated with melatonin before irradiation, 
the induction of apoptosis and p53 increased [72].
In addition to p53, COX-2 inhibition by melatonin is 
involved in the stimulation of apoptosis by melatonin [19]. 
In inflammatory conditions, due to radiation exposure, the 
expression of COX-2 as well as other anti-apoptotic genes like 
iNOS and NF-κB increases [75]. Inhibition of these inflam-
matory genes has been shown to sensitize tumor cells to 
therapeutic strategies such as radiotherapy and chemotherapy 
[109–113]. COX-2 pathway inhibition by melatonin has a syn-
ergic effect on the therapeutic effects of some other agents such 
as curcumin, fisetin, berberine and ursolic acid [114–117]. As 
a result of melatonin been a potent inhibitor of COX-2 and 
other related genes, it can sensitize COX-2 positive cancer 
cells through inhibition of COX-2 [118].
Other possible mechanisms
Stimulation of cytotoxic immune cells against tumor
Studies have shown that melatonin has the ability to enhance 
the activities of immune cells, including lymphocyte T and 
B, and natural killer (NK) cells. It has been shown that 
melatonin through various mechanisms such as stimula-
tion of proliferation of lymphocyte T, prolonged survival 
and increase in antigen presentation by macrophages boosts 
both innate and adaptive immunity [119–121]. An in vivo 
study has shown that treatment of tumor-bearing mice with 
melatonin led to a rise in NK cell numbers and consequently 
increased survival [122]. The release of IL-2 by NK cells 
plays a key role in anti-tumor activities of these cells [123]. 
There is a need to study the possible synergic effect of mela-
tonin and radiotherapy through stimulation of cytotoxic T 
and NK cells.
Suppression of inflammation and angiogenesis 
in tumor
Inflammation plays a key role in tumor resistance via stimu-
lation of pro-angiogenesis factors such as COX-2, growth 
factors such as vascular endothelial growth factor (VEGF), 
and increasing number of macrophages and T regula-
tory (Tregs) cells [79]. Both in vitro and in vivo studies 
have shown that melatonin decreases the growth of tumor 
cells via inhibition of VEGF and other growth factors like 
endothelin-1, hypoxia-inducible factor-1α (HIF-1α), epider-
mal growth factor receptor (EGFR), and insulin-like growth 
factor 1 (IGF-1) [124–127]. As exposure to a high dose of 
IR is associated with an increase in inflammatory cells and 
angiogenesis factors, modulation of this phenomenon has 
been proposed as a strategy for tumor sensitization in radio-
therapy [128] (Table 2; Fig. 2). 
Conclusion
Melatonin is a low toxic antioxidant and anti-inflammatory 
agent that has shown oncostatic effects in several studies. 
As mentioned in this review, melatonin is not just a simple 
antioxidant, it also has both radioprotective and radiosensi-
tive effects. In contrast to other conventional antioxidants, 
melatonin can modulate radiation responses via several path-
ways. In addition to direct neutralization of free radicals, 
melatonin upregulates antioxidant enzymes and suppresses 
pro-oxidant enzymes. Melatonin is a potent stimulator of 
DNA repair responses such as BER pathway genes. These 
properties of melatonin can help alleviate acute reactions 
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during radiotherapy in highly radiosensitive organs such as 
bone marrow, skin and gastrointestinal system. Melatonin 
is a potent anti-inflammatory agent that has been proposed 
for managing late effects of radiotherapy. It can modulate 
inflammation in different levels. For example, it reduces 
necrosis and apoptosis induction, suppresses TLRs, inhib-
its secretion of prostaglandins via COX-2 inhibition, and 
alleviates fibrosis via suppression of pro-fibrotic enzymes. 
Moreover, through inhibition of continuous NO production 
by iNOS, melatonin reduces genomic instability and risk of 
second primary cancers. In addition to the radioprotective 
properties of melatonin, some studies have revealed that it 
has a synergic effect with radiation on tumor cells. The most 
obvious example for radiosensitive effect of melatonin is 
its effect on breast cancer cells. Melatonin via suppression 
of estrogen in this cell can inhibit tumor proliferation and 
growth. Suppression of glycolysis and increase in oxidative 
phosphorylation by melatonin further inhibit tumor growth. 
Melatonin also promotes apoptosis in cancer cells through 
upregulation of p53 and TRAIL ligand. In addition to these 
mechanisms, other immune system mechanisms are involved 
in tumor suppressive property of melatonin. As this review 
has shown, so far, several studies have been conducted show-
ing the radioprotective effects of melatonin in different cell 
lines as well as various organs in murine. However, studies 
evaluating the radiosensitive effects of melatonin are very 
limited. Hence, further studies are needed to illustrate the 
radiosensitive effect of melatonin especially through mod-
ulation of immune system cells such as NK and T cells. 
Moreover, it is necessary to define the effect of treatment 
with melatonin on angiogenesis in both in vitro and in vivo 
studies. Clinical radioprotective effect of melatonin for ame-
lioration of dermatitis is at the first phase in breast cancer 
patients. However, so far no study has evaluated its possible 
radiosensitive effect. In future, evaluating the radiosensitive 
effect of melatonin on breast cancer may be an interesting 
Table 2  Possible mechanisms for radiosensitive effects of melatonin
Route Cells/tissues Effect Mechanisms References
In vitro Colon cancer cells, MCF-7, Suppression of angiogenesis Inhibition of VEGF, HIF-1α, IGF-1, EGFR, and 
NF-κB
[124–127]
In vitro Jurkat leukemia, MCF-7 Apoptosis induction Inhibition of COX-2, NF-κB, iNOS, and Sirt1, 
activation of p53, TGF-β
[72, 107]
In vitro MCF-7 Biosynthesis of estrogen Disrupts the binding of ERα-CaM [98, 99]
In vitro Cal-27 Elevated mitochondrial ROS production Stimulation of oxidative phosphorylation [91]
In vitro MCF-7 Suppression of DNA damage responses RAD51 and DNA-PKcs [84]
Fig. 2  Mechanisms of radio-
sensitive effect of melatonin 
on cancer cells. Melatonin 
at different levels can inhibit 
angiogenesis and tumor resist-
ance, leading to the inhibition 
of tumor cell proliferation. 
Moreover, it is possible that 
melatonin via activation of NK 
cells and cytotoxic lymphocytes 
is involved in the direct actions 
against cancer
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idea for clinical applications. The possible radioprotective 
and radiosensitive effects of melatonin on same tissue/tumor 
increase therapeutic ratio and clinical justification for its use 
as an adjuvant in radiotherapy.
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